The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

BACKGROUND: Multiple therapies exist for patients with metastatic castration-resistant prostate cancer (mCRPC). However, their improvement on progression-free survival (PFS) remains modest, potentially explained by tumor molecular heterogeneity. Several prognostic molecular biomarkers have been iden...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Trials
Asıl Yazarlar: Crippa, Alessio, De Laere, Bram, Discacciati, Andrea, Larsson, Berit, Connor, Jason T., Gabriel, Erin E., Thellenberg, Camilla, Jänes, Elin, Enblad, Gunilla, Ullen, Anders, Hjälm-Eriksson, Marie, Oldenburg, Jan, Ost, Piet, Lindberg, Johan, Eklund, Martin, Grönberg, Henrik
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Study Protocol
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318749/
https://ncbi.nlm.nih.gov/pubmed/32586393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-020-04515-8
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller